Company Overview
Company Type: Private Company
Website: www.biovectra.com
Number of Employees: 160
Year Founded: 1970
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
BIOVECTRA Inc. a contract development and manufacturing company, manufactures and supplies ingredients for pharmaceutical and biotechnology clients in the North American and European markets. Its products include bioprocessing reagents, diagnostic reagents, molecular biology reagents, and methoxy polyethylene glycol reagents. The company’s application programming interface has been used in therapeutics used to treat cancer, kidney disease, cardiovascular disease, multiple sclerosis, and many other diseases. Its support services include rapid process development and optimization, process scale-up and transfer to production facilities, critical process parameters identification and process characterization, development of process control strategies, pre-clinical, clinical, and commercial supply, and validation support. BIOVECTRA Inc. was formerly known as Diagnostic Chemicals Limited and changed its name to BIOVECTRA Inc. in December 2007. The company was founded in 1970 and is based in Charlottetown, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
31.4
EBITDA
9.1
EBIT
6.5
Cash & ST Invst.
4.5
Net Income
5.5
Total Debt
18.6
Capital Expenditure
(6.3)
Total Assets
51.6
Total Debt/EBITDA
2.0x
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Nov-30-2012 TEV and Market Cap are calculated using the last closing price

Key Professionals
Name
Title
Duffy, J. Regis
Founder and Chairman
Technow, Oliver 
CEO & President
Rogers, Gordon 
Chief Financial Officer
Doncaster, Scott
Vice President of Manufacturing Technologies & Engineering
Deighan, Valana
General Counsel
Walker, Bobbi Jo
Director of Corporate Communication
Delage, Heather
Vice President of Business Development
Wood, Lester 
Executive Director of Human Resources

Key Board Members
Name
Title
Duffy, J. Regis
Founder and Chairman
Klosk, Steven M.
Director
McCauley, Gordon C.
Director
Zisson, Alex 
Director


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
11 Aviation Avenue | Charlottetown, PE | C1E 0A1 | Canada
Fax: 902 628 2045

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
H.I.G. Capital, LLC
Sep-10-2019
Majority
-
-
-
H.I.G. BioHealth Partners
-
Unknown
-
-
Alex Zisson


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-10-2019
Nov-04-2019
Merger/Acquisition
Target
BioVectra Inc.
H.I.G. Capital, LLC
Mallinckrodt plc (OTCPK:MNKT.Q)
250.00
Jan-2-2013
Jan-18-2013
Merger/Acquisition
Target
BioVectra Inc.
Questcor Pharmaceuticals, Inc. (nka:Mallinckrodt ARD Inc.)

132.77
Nov-8-2007
Dec-3-2007
Merger/Acquisition
Seller
Diagnostic Chemicals Limited, Diagnostics Division
Genzyme Corporation Inc
Diagnostic Chemicals Limited (nka:BioVectra Inc.)
53.26
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Apr-14-2022
Business Expansions
BIOVECTRA Starts Construction on its Charlottetown mRNA Biomanufacturing Centre
Nov-18-2021
Business Expansions
BioVectra Inc. Announces Development of A Facility Specializing in the Production and Manufacturing of mRNA Vaccines and Therapeutic
Oct-21-2021
Executive/Board Changes - Other
BioVectra Inc. Appoints Steven M. Klosk and Gordon C. Mccauley to Board
Jun-02-2021
Business Expansions
Biovectra Inc. Announces New Logo, Brand and Addition to Adding New Capabilities
Mar-11-2021
Client Announcements
Phasebio Pharmaceuticals and Biovectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab


Advisors
Most Recent Auditor
Arsenault Best Cameron Ellis


Most Recent Auditor
ArsenaultBestCameronEllis


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 22, 2023 06:21 AM
BioVectra Inc.
BioVectra Inc
Reports
74
GlobalData

Aug 29, 2023 01:51 AM
BioVectra Inc.
BioVectra Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Jun 15, 2023 02:10 AM
BioVectra Inc.
BioVectra Inc
Reports
71
GlobalData

May 17, 2023 05:35 AM
BioVectra Inc.
BioVectra Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Mar 17, 2023 03:02 AM
BioVectra Inc.
BioVectra Inc
Reports
71
GlobalData

Feb 10, 2023 05:20 AM
BioVectra Inc.
BioVectra Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Dec 27, 2022 03:03 AM
BioVectra Inc.
BioVectra Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
28
GlobalData

Dec 14, 2022 02:32 AM
BioVectra Inc.
BioVectra Inc
Reports
71
GlobalData

Sep 21, 2022 06:25 AM
BioVectra Inc.
BioVectra Inc
Reports
70
GlobalData

Aug 29, 2022 05:15 AM
BioVectra Inc.
BioVectra Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
27


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Contract Manufacturing Services, DispersinB (Future), Prolanta (Future)


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Dec-13-2017
Dec-11-2017
BioVectra Inc.
SEC
8-K (1.01)
19 KB
Mar-03-2014
Feb-25-2014
Mallinckrodt ARD Inc.
SEC
8-K (2.02, 9.01)
8 MB
May-06-2013
Apr-30-2013
Mallinckrodt ARD Inc.
SEC
8-K (2.02, 9.01)
2 MB
Apr-03-2013
Jan-18-2013
Mallinckrodt ARD Inc.
SEC
8-K/A (2.01, 9.01)
1 MB
Mar-04-2013
Feb-26-2013
Mallinckrodt ARD Inc.
SEC
8-K (2.02, 9.01)
4 MB
Jan-18-2013
Jan-18-2013
Mallinckrodt ARD Inc.
SEC
8-K (2.01, 9.01)
18 KB
Jan-04-2013
Jan-02-2013
Mallinckrodt ARD Inc.
SEC
8-K (1.01, 8.01, 9.01)
46 KB
Jan-05-2007
-
BioVectra Inc.
SEDAR
News Releases
93 KB

Key Board Members Details
Name
Title
Phone
Fax
Email
Duffy, J. Regis
Founder and Chairman
-
902 628 2045

Klosk, Steven M.
Director
-
902 628 2045

McCauley, Gordon C.
Director
-
902 628 2045

Zisson, Alex 
Director
(203) 428-3905
902 628 2045
azisson@higcapital.com
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Duffy, J. Regis
Founder and Chairman
-
902 628 2045

Technow, Oliver 
CEO & President
-
902 628 2045
otechnow@biovectra.com
Rogers, Gordon 
Chief Financial Officer
-
902 628 2045
grogers@biovectra.com
Doncaster, Scott
Vice President of Manufacturing Technologies & Engineering
-
902 628 2045
sdoncaster@biovectra.com
Deighan, Valana
General Counsel
-
902 628 2045
vdeighan@biovectra.com
Walker, Bobbi Jo
Director of Corporate Communication
(902) 218-7649
902 628 2045
bwalker@biovectra.com
Delage, Heather
Vice President of Business Development
-
902 628 2045
hdelage@biovectra.com
Wood, Lester 
Executive Director of Human Resources
-
902 628 2045
lwood@biovectra.com
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
